Additional Information

Additional Information

Important Notices

  • Please wear your name badge at all times, including the Thursday Reception. 

CME Credit Information

  • The Pacific Coast Oto-Ophthalmological Society is accredited by the Institute for Medical Quality / California Medical Association (CMA) to provide continuing medical education for physicians.
  • The Pacific Coast Oto-Ophthalmological Society takes responsibility for the content, quality, and scientific integrity of this CME activity.
  • This educational activity has been designated for a maximum of:
    15 AMA PRA Category 1 Credits™
  • Physicians should claim only the credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.

Claiming CME Credit

To receive CME credit:

  • You must sign in each day 
  • Complete all required evaluations for all 15 credits

Certificates will be emailed within two weeks following the meeting.

If you require your certificate sooner, please contact Denise.

Evaluation Forms

It is very important to complete evaluation forms for all sessions you attend.

  • Please remember to sign in each day 
  • Our continued CME accreditation depends on participant feedback 
  • Evaluations help us improve future programs 
  • For ABO Certification, your name must appear on the form 
  • Please use the QR code provided to complete evaluations after each talk
  • View the Evaluation Forms

Educational Objectives

It is necessary for physicians to be kept abreast of new and constantly changing techniques and technologies in medicine in order to facilitate improved patient care.

The June 2026 Pacific Coast Oto-Ophthalmological Society (PCOOS) program is intended to provide practicing ophthalmologists and otolaryngologists with an annual update across the various subspecialties of ophthalmology and otolaryngology.

Speakers will provide clinical and evidence-based updates in a setting conducive to learning. Didactic lectures and case presentations will reinforce best practice management strategies.

Learning Objectives

Upon completion of this activity, participants are expected to improve their ability to:

  • Incorporate new techniques, medical therapies, diagnostic tests, and procedures in the management and treatment of ophthalmology and otolaryngology patients to improve quality of care
  • Integrate best available evidence and recent clinical research into patient assessment and treatment approaches
  • Improve clinical confidence through application of recent advances in ophthalmology and otolaryngology
  • Recognize current clinical controversies in ophthalmologic and otolaryngologic care and critically evaluate emerging evidence
  • Enhance ability to consult with colleagues and patients regarding evolving treatments, including new devices, technologies, and pharmaceuticals

Disclosure & Conflict of Interest Policy

As a provider accredited by ACCME and CMA, the Pacific Coast Oto-Ophthalmological Society (PCOOS) ensures balance, independence, objectivity, and scientific rigor in all sponsored educational activities. PCOOS adheres to the ACCME Standards for Commercial Support: Standards to Ensure Independence of CME Activities (effective September 2004).

Disclosure Review Process

Upon receipt of each disclosure form, the Program Chair and the Executive Secretary-Treasurer review both the disclosure form and the program “Call” to determine whether any personal conflicts of interest exist.

For individuals identified with a personal conflict of interest:

  • The Program Chair and Executive Secretary-Treasurer evaluate the conflict in relation to the individual’s role. 
  • Appropriate steps are taken to resolve the conflict of interest. 
  • A speaker may be required to present an alternate lecture topic that does not present a conflict. 

Alternate Oversight Procedures

If a conflict of interest involves key leadership roles, the following substitutions apply:

  • If the Program Chair or Program Committee members have a conflict, the Executive Secretary-Treasurer and the President assume responsibility. 
  • If the Executive Secretary-Treasurer has a conflict, the President and the Program Chair assume responsibility. 

Learner Disclosure

For each presentation in the program, learners are asked to:

  • Indicate on the evaluation instrument whether they observed any conflict of interest 
  • Provide comments regarding any perceived conflict

Disclosure of Financial Relationships

  • The following speakers have indicated a financial interest, arrangement, or other relationship with ineligible companies discussed in this continuing medical education (CME) activity, or are presenting information on investigational or off-label use of pharmaceutical products or medical devices.


Aaron Nagiel: Eyebiotech: Consultant; Cellio: Consultant, Ownership, Royalties for patent licensing; AA Vantgarde: Consultant: Epicrispr: Consultant; Blue Rock: Consultant, Grant Support; Beacon Therapeutics: Consultant, Grant Support; Janssen: Consultant; Endogena: Consultant; Opus Genetics: Consultant, Grant Support; Blue Gen: Consultant; Ultragenyx: Consultant; Immuneering: Consultant; Novartis: Consultant; Alia Tx: Consultant; Asena: Grant Support; Janssen: Grant Support; Raresight: Consultant, Ownership; Boxer Capital: Consultant; Goldman Life Science: Consultant; Vida Ventures: Consultant; Sunregen: Consultant

Brian Chan-Kai: 4D Medical: Consultant; Abbvie: Consultant; Amgen: Consultant; Apellis: Consultant; Harrow: Consultant; Genentech: Consultant; Neurotech: Consultant; Regeneron: Consultant

C. Ellis Wisely: Glaukos: Consultant Dompe: Consultant

Charles Eifrig: Alcon: Consultant; Genentech: Consultant

Evan Kalin-Hajdu: Roche Pharmaceuticals: Member of the Independent Data Committee for Phase 3 Trials GP44467 & GP44729

Frank Brodie: Long Bridge Medical: Co-Founder, Equity, Consultant, Patents; Science Corp: Consultant, Equity; OnPoint Medical: Consultant; Genentech: Consultant, Research; Abbvie: Consultant

Laura Kopplin: Priovant: Primary Investigator; Roche: Primary Investigator

Matthew Simunovic: Longbridge Medical: Research Trial Funding (ENDED); Science Corp: Research Trial Funding; Neurotech Pharmaceuticals: Research Trial Funding; Roche: Research Trial Funding, Speaker Fees; Apellis: Consultant (ENDED); ADDARx: Research Trial Funding (ENDED)

Nisha Acharya: Genentech: Consultant

Randall Ow: Sanofi-Regeneron: Speakers Bureau; Medtronic: Consultant, Advisory Board; Aerin Medical: Principal Investigator; Liva Nova: Investigator; GSIC: Speakers Bureau; Neurent: Investigator; Optinose: Consultant, Speakers Bureau

Sophie Liao: Immunovant: Research Protocol SUB-Investigator; Tourmaline: Research Protocol SUB-Investigator; Viridian: Research Protocol SUB-Investigator; Kriya Therapeutics: Research Protocol SUB-Investigator; Physicians Education Resource: Session Lead Organizer – Envision Summit

Corporate Sponsors & Exhibitors

The Pacific Coast Oto-Ophthalmological Society gratefully acknowledges and thanks our Corporate Sponsors and Exhibitors for their generous support of this educational program.

Their contributions help make this continuing medical education activity possible while maintaining independence, balance, and scientific integrity.

Platinum Sponsors

  • GENENTECH – OPH
  • SMITH & NEPHEW
  • REGENERON – ENT

Gold Sponsors

  • Alcon
  • Harrow
  • Regeneron – OPH
  • Stryker

Silver Sponsors

  • Karl Storz Surgical

Bronze Sponsors

  • Ani Pharmaceuticals
  • Apellis Pharmaceuticals Inc
  • Astellas
  • Aerin
  • Coast Surgical
  • Medically USA
  • Olympus

Pacific Coast Oto-Ophthalmological Society

Founded in 1906, PCOOS is one of the oldest medical societies in the western United States.

PCOOS is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.